This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
by Zacks Equity Research
It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news also continued to be in the spotlight.
GSKNegative Net Change INCYNegative Net Change BIOANegative Net Change QUREPositive Net Change CRDFPositive Net Change
biotechnology biotechs medical pharmaceuticals
5 High ROE Stocks to Buy as Volatility Weighs on Markets
by Supriyo Bose
DIS, LDOS, RF, FTNT and JAZZ are some of the stocks with high ROE to profit from as intense volatility spooks markets.
RFNegative Net Change DISPositive Net Change JAZZPositive Net Change FTNTPositive Net Change LDOSNegative Net Change
biotechnology consumer-discretionary finance tech-stocks
Bristol Myers Stock Surges 36.5% in Six Months: Time to Buy or Sell?
by Ekta Bagri
Bristol Myers stock has witnessed a stupendous rally in the past six months. We believe there is more room for growth, and any dip in the share price can be used as a buying opportunity.
BMYPositive Net Change PFENegative Net Change GILDNegative Net Change
biotechnology biotechs dividend-yield medical pharmaceuticals
ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?
by Ekta Bagri
ADMA Biologics has performed phenomenally in 2024. Given its strong trajectory, we recommend investors use any dip in the stock price as a buying opportunity.
GRFSNegative Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Editas Stock Rises on Updated Data From SCD Study of Reni-Cel
by Zacks Equity Research
EDIT's stock gains on updated positive safety and efficacy data from the phase I/II/III RUBY study of its lead candidate, reni-cel, for severe SCD.
PFENegative Net Change GILDNegative Net Change HALOPositive Net Change EDITNegative Net Change
biotechnology biotechs medical pharmaceuticals
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential
by Zacks Equity Research
Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications.
PFENegative Net Change GILDNegative Net Change HALOPositive Net Change KODNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
by Zacks Equity Research
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 therapies.
NVSPositive Net Change PFENegative Net Change PTCTNegative Net Change OLMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals
by Zacks Equity Research
INCY's phase III study, evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer, meets primary and secondary endpoints.
GSKNegative Net Change INCYNegative Net Change CSTLPositive Net Change IMCRPositive Net Change
biotechnology biotechs pharmaceuticals
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD
by Zacks Equity Research
The FDA accepts GSK's regulatory filing seeking the expanded use of Nucala in COPD treatment for review.
GSKNegative Net Change ALNYPositive Net Change PFENegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
XLONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Walt Disney (DIS) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
DISPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Porch Group, Inc. (PRCH)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PRCHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Denali Starts Dosing in Phase II Parkinson's Disease Study
by Zacks Equity Research
DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing.
SNYPositive Net Change BIIBPositive Net Change SPRONegative Net Change DNLIPositive Net Change
biotechnology biotechs medical pharmaceuticals
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
by Zacks Equity Research
Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.
ALNYPositive Net Change PFENegative Net Change GILDNegative Net Change TARANegative Net Change
biotechnology biotechs cell-therapy medical oncology-screening pharmaceuticals
4 Crypto-Focused Stocks to Grab as Bitcoin Roars Past $100,000
by Ritujay Ghosh
Stocks like NVDA, BLK, COIN and SHOP are poised to gain from the ongoing Bitcoin rally.
BLKNegative Net Change NVDANegative Net Change SHOPNegative Net Change COINNegative Net Change
biotechnology bitcoin blockchain cryptocurrency
Should You Buy Amprius Technologies (AMPX) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
AMPXNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
FDA Accepts Roche's Columvi sBLA for Expanded Use in Lymphoma
by Zacks Equity Research
The FDA accepts RHHBY's sBLA seeking the label expansion of Columvi to include the treatment of second-line R/R DLBCL for review.
RHHBYPositive Net Change PFENegative Net Change GILDNegative Net Change HALOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug
by Zacks Equity Research
CYTK opens enrollment in the phase III COMET-HF study on omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction.
BAYRYPositive Net Change CYTKNegative Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
PCRX Receives New Patent for Lead Pain Drug Exparel in the US
by Zacks Equity Research
The U.S. Patent and Trademark Office grants a new patent to protect the chemical composition of Pacira's lead pain-management drug, Exparel.
PFENegative Net Change GILDNegative Net Change PCRXNegative Net Change ALLOPositive Net Change
biotechnology biotechs medical pharmaceuticals
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
by Zacks Equity Research
Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants.
PFENegative Net Change GILDNegative Net Change ALLOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC
by Zacks Equity Research
GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.
GSKNegative Net Change MRKPositive Net Change GILDNegative Net Change MRUSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
by Zacks Equity Research
NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.
NVSPositive Net Change PFENegative Net Change PTCTNegative Net Change OLMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Accepts Cytokinetics' Application for Cardiovascular Drug
by Zacks Equity Research
CYTK's NDA is seeking approval for the lead pipeline candidate, aficamten, which the FDA accepted and assigned a target action date of Sept. 26, 2025.
BAYRYPositive Net Change CYTKNegative Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
by Zacks Equity Research
Purple Biotech stock surges 150.4% on reporting superior efficacy data from the mid-stage study of its combo therapy on pancreatic cancer patients.
BMYPositive Net Change PFENegative Net Change GILDNegative Net Change PPBTNo Net Change
biotechnology biotechs medical pharmaceuticals
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals
by Zacks Equity Research
Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.
RHHBYPositive Net Change PFENegative Net Change GILDNegative Net Change NVCRPositive Net Change
biotechnology biotechs medical pharmaceuticals